The future of oncology - unleashing the power lying within us

Conventional anticancer drugs were designed based on the rapid division of tumor cells. However, the malignant transformation is not the only reason for intense proliferation and the collateral damage done to normal cells results in adverse side effects which can even decrease the overall survival. Thus cytotoxic agents are notoriously hard to get through clinical trials resulting in about 95% attrition rates for this drugs [1].